Page last updated: 2024-08-25

rosiglitazone and Abdominal Aortic Aneurysm

rosiglitazone has been researched along with Abdominal Aortic Aneurysm in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, YX; Sun, R; Wang, WD	1
Cockerill, GW; Deb, R; Dunkley, M; Gaze, D; Gnaneswaran, Y; Howe, F; Jones, A; Loftus, IM; Nasr, H; Thompson, MM; Torsney, E	1
Cockerill, GW; Pirianov, G; Torsney, E	1

Reviews

1 review(s) available for rosiglitazone and Abdominal Aortic Aneurysm

Article	Year
Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection? Current vascular pharmacology, 2013, Volume: 11, Issue:3 Topics: Animals; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Molecular Targeted Therapy; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones	2013

Article

Year

Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?

Current vascular pharmacology, 2013, Volume: 11, Issue:3

Topics: Animals; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Molecular Targeted Therapy; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones

2013

Other Studies

2 other study(ies) available for rosiglitazone and Abdominal Aortic Aneurysm

Article	Year
PPARγ agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation. Molecular medicine reports, 2018, Volume: 18, Issue:3 Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Disease Models, Animal; Inflammation; Male; Mice; Mice, Knockout; Models, Biological; PPAR gamma; Rosiglitazone; Th2 Cells; Thiazolidinediones; Vasodilator Agents	2018
Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation, 2009, Jun-23, Volume: 119, Issue:24 Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Blood Glucose; Body Weight; Cholesterol; Disease Models, Animal; E-Selectin; Humans; Hypercholesterolemia; Hypoglycemic Agents; Interleukin-6; Mice; Mice, Knockout; PPAR gamma; Receptors, Angiotensin; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2009

Article

Year

PPARγ agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation.

Molecular medicine reports, 2018, Volume: 18, Issue:3

Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Disease Models, Animal; Inflammation; Male; Mice; Mice, Knockout; Models, Biological; PPAR gamma; Rosiglitazone; Th2 Cells; Thiazolidinediones; Vasodilator Agents

2018

Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.

Circulation, 2009, Jun-23, Volume: 119, Issue:24

Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Blood Glucose; Body Weight; Cholesterol; Disease Models, Animal; E-Selectin; Humans; Hypercholesterolemia; Hypoglycemic Agents; Interleukin-6; Mice; Mice, Knockout; PPAR gamma; Receptors, Angiotensin; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha

2009